QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024 adjusted EPS outlook

Q3 2024: Net sales of $502 million (+5% actual rates, +6% constant exchange rates, CER); diluted EPS of $0.44 and adjusted diluted EPS of $0.57 // Net sales of $502 million CER ahead of outlook for at least $495 million CER and adjusted diluted EPS of $0.58 CER ahead of outlook for at least $0.55 CER // +10% CER growth in Diagnostic solutions leads results among product groups // 29.6% adj. operating income margin up 3 percentage points vs. 26.6% in Q3 2023 // Free cash flow up 73% to $364 million in first nine months of 2024 vs. same 2023 period // FY 2024 net sales outlook reaffirmed for at least $1.985 billion CER on solid core business trends; adj. diluted EPS outlook increased to at least $2.19 CER Q3 2024: Net sales of $502 million (+5% actual rates, +6% constant exchange rates, CER); diluted EPS of $0.44 and adjusted diluted EPS of $0.57 // Net sales of $502 million CER ahead of outlook for at least $495 million CER and adjusted diluted EPS of $0.58 CER ahead of outlook for at least $0.55 CER // +10% CER growth in Diagnostic solutions leads results among product groups // 29.6% adj. operating income margin up 3 percentage points vs. 26.6% in Q3 2023 // Free cash flow up 73% to $364 million in first nine months of 2024 vs. same 2023 period // FY 2024 net sales outlook reaffirmed for at least $1.985 billion CER on solid core business trends; adj. diluted EPS outlook increased to at least $2.19 CER